Selskabets formål er at drive fabrikation og virksomhed i forbindelse hermed
| Year | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 2025 | 2.6 mia. | 1.6 mia. | 4.7 mia. | 2.2 mia. | 240 | |
CVR: 15517085
Secondary names: SOLOCHEM A/S, PHARMACOSMOS PHARMACEUTICALS A/S, NEBO A/S
Claes Christian Strøm joined as director
Compared to 131 companies in Fremstilling af farmaceutiske præparater
Comparison is based on industry median values
PHARMACOSMOS A/S demonstrates a strong financial recovery and growth trajectory, with revenue increasing significantly from 782 million DKK in 2021 to 2.623 billion DKK in 2025. Profitability has also improved markedly, shifting from a loss of 136 million DKK in 2021 to a profit of 1.622 billion DKK in 2025, indicating enhanced operational efficiency and market demand. The company's equity has risen steadily, reaching 2.197 billion DKK in 2025, which reflects a solid balance sheet and a robust position within the pharmaceutical manufacturing industry. However, the rapid growth in revenue and profit raises questions about sustainability and potential market saturation in the future.
AI-generated summary
Companies in the same industry and area
companydata.dk